Interleukin-29 induces epithelial production of CXCR3A ligands and T-cell infiltration

[1]  P. E. Van den Steen,et al.  CXCR3 ligands in disease and therapy. , 2015, Cytokine & growth factor reviews.

[2]  J. Yewdell,et al.  CXCR3 chemokine receptor enables local CD8(+) T cell migration for the destruction of virus-infected cells. , 2015, Immunity.

[3]  Maxim N. Artyomov,et al.  Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity , 2015, Science.

[4]  T. Hassanein,et al.  A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. , 2014, Journal of hepatology.

[5]  R. Sabat,et al.  Pathogenesis of psoriasis , 2014 .

[6]  H. Volk,et al.  Deficient Cutaneous Antibacterial Competence in Cutaneous T-Cell Lymphomas: Role of Th2-Mediated Biased Th17 Function , 2014, Clinical Cancer Research.

[7]  X. Man,et al.  Targeting VEGF/VEGFR in the treatment of psoriasis. , 2014, Discovery medicine.

[8]  Z. Kraft,et al.  Pegylated interferons Lambda‐1a and alfa‐2a display different gene induction and cytokine and chemokine release profiles in whole blood, human hepatocytes and peripheral blood mononuclear cells , 2014, Journal of viral hepatitis.

[9]  Andrew Johnston,et al.  Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides insights into disease mechanisms , 2014, The Journal of investigative dermatology.

[10]  G. Kollias,et al.  Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis-like skin inflammation in mice. , 2013, Immunity.

[11]  M. Raftery,et al.  IL-29 Is Produced by TH17 Cells and Mediates the Cutaneous Antiviral Competence in Psoriasis , 2013, Science Translational Medicine.

[12]  D. Kavanagh,et al.  CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver , 2012, Journal of hepatology.

[13]  R. Gallo,et al.  The antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury. , 2012, Immunity.

[14]  A. Casrouge,et al.  Discrimination of agonist and antagonist forms of CXCL10 in biological samples , 2012, Clinical and experimental immunology.

[15]  H. Volk,et al.  Deficiency of IL-22 Contributes to a Chronic Inflammatory Disease: Pathogenetic Mechanisms in Acne Inversa , 2011, The Journal of Immunology.

[16]  Christian A. Luber,et al.  Mouse CD8α+ DCs and human BDCA3+ DCs are major producers of IFN-λ in response to poly IC , 2010, The Journal of experimental medicine.

[17]  Todd Davidson,et al.  Generation of Pathogenic Th17 Cells in the Absence of TGF-β Signaling , 2010, Nature.

[18]  R. Sabat,et al.  Interleukin-28 and interleukin-29: novel regulators of skin biology. , 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[19]  R. Sabat,et al.  IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. , 2010, Cytokine & growth factor reviews.

[20]  P. Liang,et al.  IL-24 Transgenic Mice: In Vivo Evidence of Overlapping Functions for IL-20, IL-22, and IL-24 in the Epidermis , 2010, The Journal of Immunology.

[21]  K. Asadullah,et al.  The Th17 cytokine IL‐22 induces IL‐20 production in keratinocytes: A novel immunological cascade with potential relevance in psoriasis , 2009, European journal of immunology.

[22]  A. C. Looman,et al.  Despite IFN-λ receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines , 2009, Genes and Immunity.

[23]  P. Duquette,et al.  Preferential recruitment of interferon‐γ–expressing TH17 cells in multiple sclerosis , 2009, Annals of neurology.

[24]  H. Volk,et al.  IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not , 2009, Journal of Molecular Medicine.

[25]  L. Cosmi,et al.  Phenotypic and functional features of human Th17 cells , 2007, The Journal of experimental medicine.

[26]  D. Jarrossay,et al.  Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells , 2007, Nature Immunology.

[27]  S. Sa,et al.  The Effects of IL-20 Subfamily Cytokines on Reconstituted Human Epidermis Suggest Potential Roles in Cutaneous Innate Defense and Pathogenic Adaptive Immunity in Psoriasis , 2007, The Journal of Immunology.

[28]  Kathleen M. Smith,et al.  IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis , 2006, The Journal of experimental medicine.

[29]  L. Glimcher,et al.  T-bet Controls Pathogenicity of CTLs in the Heart by Separable Effects on Migration and Effector Activity1 , 2006, The Journal of Immunology.

[30]  L. Fouser,et al.  Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides , 2006, The Journal of experimental medicine.

[31]  Kevin Wei,et al.  A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development , 2006, The Journal of experimental medicine.

[32]  K. Asadullah,et al.  IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis , 2006, European journal of immunology.

[33]  S. Smirnov,et al.  Characterization of the mouse IFN-λ ligand-receptor system: IFN-λs exhibit antitumor activity against B16 melanoma , 2006 .

[34]  K. Asadullah,et al.  IL-22 increases the innate immunity of tissues. , 2004, Immunity.

[35]  E. Coccia,et al.  Viral infection and Toll‐like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte‐derived dendritic cells , 2004, European journal of immunology.

[36]  Sergio Romagnani,et al.  An Alternatively Spliced Variant of CXCR3 Mediates the Inhibition of Endothelial Cell Growth Induced by IP-10, Mig, and I-TAC, and Acts as Functional Receptor for Platelet Factor 4 , 2003, The Journal of experimental medicine.

[37]  M. Parmentier,et al.  Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. , 2001, Blood.

[38]  E Lazzeri,et al.  Interferon-inducible protein 10, monokine induced by interferon gamma, and interferon-inducible T-cell alpha chemoattractant are produced by thymic epithelial cells and attract T-cell receptor (TCR) alphabeta+ CD8+ single-positive T cells, TCRgammadelta+ T cells, and natural killer-type cells in hum , 2001, Blood.

[39]  J. Flier,et al.  Genomic organization, sequence and transcriptional regulation of the human CXCL 11(1) gene. , 1999, Biochimica et biophysica acta.

[40]  R. Rabin,et al.  Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. , 1999, Journal of immunology.

[41]  James G. Boyd,et al.  Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3 , 1998, The Journal of experimental medicine.

[42]  C. Mackay,et al.  The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. , 1998, The Journal of clinical investigation.

[43]  P. Allavena,et al.  Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.

[44]  Simon A. Jones,et al.  Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes , 1996, The Journal of experimental medicine.

[45]  T. Bieber,et al.  Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNλ) in cutaneous lupus erythematosus. , 2011, The Journal of investigative dermatology.

[46]  E. Wolf,et al.  Beyond Wavy Hairs The Epidermal Growth Factor Receptor and Its Ligands in Skin Biology and Pathology , 2010 .

[47]  S. Smirnov,et al.  Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. , 2006, Cancer research.

[48]  J. Schröder,et al.  Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection , 2005, Nature Immunology.

[49]  A. Lewis-Antes,et al.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. , 2003, Nature immunology.

[50]  Scott R. Presnell,et al.  IL-28, IL-29 and their class II cytokine receptor IL-28R , 2002, Nature Immunology.